09:37 AM EDT, 08/01/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Friday said its net loss widened in the first-quarter.

The net loss rose to $4.9 million or $0.06 per share compared, from $3.6 million or $0.05 per share for the prior year period.

R&D expenses increased by $1.4 million, to $4.2 million, due to higher costs related to the expansion of the MDNA11 ABILITY-1 study to new clinical sites and the inclusion of more patients in the study.

Medicenna exited the quarter with $20.5 million in cash, enough to fund operations through the middle of next year.

The company's shares are down $0.02, to $0.84, on the Toronto Stock Exchange.

Price: 0.84, Change: -0.02, Percent Change: -2.33